

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/22, A61P 9/12, 35/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/27387</b> <b>(43) International Publication Date:</b> 18 May 2000 (18.05.00)
<b>(21) International Application Number:</b> PCT/IT99/00357 <b>(22) International Filing Date:</b> 9 November 1999 (09.11.99)  <b>(30) Priority Data:</b> PCT/IT98/00318 11 November 1998 (11.11.98) IT RM98A000701 11 November 1998 (11.11.98) IT  <b>(71) Applicant (for all designated States except US):</b> SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Skakespeare, 47, I-00144 Rome (IT).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CALVANI, Menotti [IT/IT]; Via Longanesi, 14, I-00146 Rome (IT). PISANO, Claudio [IT/IT]; Via San Michele, 30, I-04011 Aprilia (IT).  <b>(74) Agent:</b> SPADARO, Marco; Sigma-Tau Industrie Farmaceu- tiche Riunite S.p.A., Viale Shakespeare, 47, I-00144 Rome (IT).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT CAPABLE OF INDUCING APOPTOSIS  <b>(57) Abstract</b>  The present invention relates to the use of propionyl L-carnitine and the pharmaceutically acceptable salts thereof for the preparation of medicaments useful in the treatment of pathologies whose treatment gains a benefit from inducement of apoptosis, in particular blood vessels, such as restenosis after angioplasty or coronary stenting, or in particular tumours.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Use of propionyl L-carnitine for the preparation of a  
medicament capable of inducing apoptosis.**

The present invention relates to the use of propionyl L-carnitine and the pharmaceutically acceptable salts thereof for the  
5 preparation of medicaments useful in the treatment of pathologies whose treatment gains a benefit from inducement of apoptosis, in particular blood vessels, such as restenosis after angioplasty or coronary stenting, or in particular tumours.

**Background of the invention.**

10 **Cell proliferation in circulatory diseases**

A number of studies demonstrated that cell proliferation plays a pivotal role in atherosclerosis, hypertension pathogenesis and restenosis after angioplasty or coronary stenting (Ross, 1976; Schwartz, 1990).

15 Many experimental studies, carried out on human atherosclerotic plaques, demonstrated that cell proliferation is a determining phenomenon both in the early phases and in the progression of the plaque.

Further, proliferation of smooth muscle cells, which migrated  
20 to intima from vascular tunica media, represents cell basis of coronaric restenosis after rivascularization processes through angioplasty or dilatation by means of a stent.

This drawback is the major limit to the application of percutaneous rivascularization in patients affected by acute

coronary syndromes, since it is responsible for about 40% of post-surgical failures (Holmes et al., 1984).

Therefore, making available substances capable of controlling the proliferation of smooth muscular cells of vessel wall is a goal of primary importance in the prevention of restenosis after angioplasty,  
5 as the proliferative phenomenon occurs in a determined timed corresponding to the first weeks following the intervention.

Proliferation control in experimental atherosclerotic lesions has been obtained with cytostatic drugs, such as etoposide (Llera-Moya  
10 et al., 1992), with steroid hormones (Cavallero et al.; 1971; 1973; 1975; 1976), progestinic hormones (Spagnoli et al., 1990), dexamethasone (Asai et al., 1993).

Smooth muscle cell proliferation is also inhibited by calcium antagonist substances due both to a decrease of DNA synthesis,  
15 such as in case of verapamil (Stein et al., 1987) and to the interference in second messenger systems (cAMP), as demonstrated for nifedipine (Cheung et al., 1987).

The treatment with ACE-inhibitors resulted in the control of the growth of intima thickening (Powell, 1989).

20 Other in-vitro studies evidenced an antiproliferative effect on cultured smooth muscular cells of rat aorta given by simvastatine, a HMG-CoA reductase inhibitor, used as hypolipidemic agent (Corsini et al., 1991). Further, some substances having triglyceridhaemia lowering effect, such as fibrates, showed to be able to prevent the

progression of atherosclerotic lesions in the human (Olsson et., 1990).

In a manner similar to what observed in neoplasia (Kerr, 1994), phenomena of population decrease are observed to occur together  
5 with cell proliferation in atherosclerotic population and/or in intima thickening (Gabbiani, 1995), thus suggesting that highly proliferative cells go toward apoptosis and that modulation of the latter plays an important role in atherosclerotic lesion genesis.

Apoptosis has been demonstrated in various forms of human  
10 and experimental cardiovascular diseases (Sharifi AM, Schriffin EL; Am. J. Hypertens. 1998, Sep; 11(9): 1108-16).

Angioplasty initiates a number of responses in the vessel wall including cellular migration, proliferation, and matrix accumulation, all of which contribute to neointima formation and restenosis (Malik  
15 N et al; Circulation 1998 Oct 20; 98(16): 1657-65). Inducing apoptosis may be beneficial also to reverse vascular disease, as pulmonary vascular disease (Cowan K. N. et al. Circ. Res. 1999 May 28; 84(10): 1223-33). Restenosis after angioplasty is due to damaged intima cells.

20 Using apoptosis inducing substances, for example for treating tumors, bears the risk to provoke a generalised phenomenon, with possible side effects, which can be even very severe, such as in the case of stem cells.

There is the necessity to find a propaptotic agent devoid of  
25 generalised phenomenon.

Proposals for preventing restenosis can be found, for example in US 5116864 and US 5835935.

#### Apoptosis in tumours

It is well-known that the use of anticancer agents in human  
5 therapy causes a large number of toxic or side effects which may be life-threatening for the patients. These complications, in fact, may lead to a reduction in the doses of the agents, and occasionally to discontinuation of the therapy itself.

Reduction of the dose or discontinuation of the therapy in  
10 many cases causes a deterioration of the individual's general condition because it favours the development of relapses, with consequences which are sometimes fatal for the patient.

The growing number and importance of the anticancer agents used in human therapy, the main limitation of which continues to  
15 be the occurrence of toxic or side effects, mean that this problem is still a matter for considerable concern.

Thus, the discovery of new agents or new, appropriate combinations of different agents capable of substantially reducing the toxic or side effects caused by anticancer agents used in human  
20 therapy is much to be desired.

One of the general problems of pharmacological therapy is the therapeutic index of the agents, that is to say the ratio of the therapeutically effective dose to the toxic dose, or, at any rate, the dose that gives rise to the onset of side effects.

The medical community still perceives the need for therapeutic regimens which allow the patient to face up to the treatment, which, in the case of anticancer chemotherapy is particularly hard to support, while at the same time conserving an acceptable quality of life. These considerations also apply to the therapeutic treatment of animals, for instance, so-called pets.

The natural tendency to reduce the doses, and thus the use of pharmaceutical forms suitable for therapeutically useful administrations without obliging the patient to take the agents too often, contrasts with the minimum effective doses typical of each anticancer agent.

Thus a substance capable of intervening on the tumour cell, even if devoid of a true cytotoxic activity, but capable of exerting an effect with the antitumour drug, for example inducing apoptosis in the tumour cell, would be of great benefit.

It has now been found that propionyl L-carnitine, thanks to its unexpected proapoptotic effect, is endowed with a specific action of control on smooth muscular cells of vessels and on tumor cells.

#### **Abstract of the invention.**

It is an object of the present invention the use of propionyl L-carnitine and the pharmacologically acceptable salts thereof for the preparation of a medicament useful in the treatment of pathologies whose treatment gains a benefit from inducement of apoptosis, in particular blood vessels, such as restenosis after angioplasty or coronary stenting, or in particular tumors.

The most important and surprising advantage of the present invention is that the administration of propionyl L-carnitine does not imply toxic effects on bone marrow and in gut, which have a good production of blood cellular elements and a very good turnover of intestinal mucosa cells, respectively. This and other aspects of the present invention will be illustrated in detail, also by means of examples.

Propionyl L-carnitine has been described as preventing the progression of atherosclerotic lesions in aged hyperlipemic rats (Spagnoli L.G., Orlandi A., Marino B., Mauriello A., De Angelis C., Ramacci M.T., *Atherosclerosis* 1995; 114, 29-44). In this study, the authors demonstrate the strong antiatherogenic effect of propionyl L-carnitine (also named PLC). This effect, although demonstrated in rabbits, admittedly a model not applicable to man, was elucidated through a lipid lowering effect. In fact, the authors state "Although the number of [...] animals was not very high, it was enough to evidence a strongly significant decrease of total triglycerides, IDL- and VLDL-triglycerides [...], while the plasma cholesterol level was slightly and transiently modified" (page 40, left-hand column, lines 16-19). The authors also observed a lower level of proliferative activity in both macrophages and SMC composing the plaques (*ibid*, last 5 lines). The authors then declare that "at present, we cannot assume that PLC has any therapeutic application" (*ibid*, right-hand column, first 3 lines). However, the results of that study allowed to establish the atherogenic role of  $\beta$ -VLDL in the progression and/or



transformation of age-related myointimal thickening in fibroatheromatous plaques (ibid, lines 5-10). The authors provide the hypothesis that plasma triglyceride levels is directly related to the proliferative activity of plaque cell population and that the pharmacological regulation of these two factors may be associated with the marked reduction of the plaque progression in aged hypercholesterolemic rabbits. Also it is stated that some experimental data support the hypothesis of a relationship between triglycerides and cellular proliferation (ibid, page 41, right-hand column, lines 20-29). The authors conclude that "PLC does not seem to act through the modulation of the expression of [...] growth factor" (ibid, last two lines) and that "further in vitro studies are needed in order to answer the question whether or not PLC exerts a direct control on cell proliferation of atherosclerotic plaques" (ibid, page 42, last for lines).

The teaching of this work is that PLC prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits acting as hypolipidemic agent. Thus, lowering the lipid, which is responsible for cell proliferation of atherosclerotic plaques, PLC indirectly acts as antiatherogenic agent. No antiproliferative action was demonstrated for PLC.

#### **Detailed description of the invention.**

The present invention is based on the application of the discovery that propionyl L-carnitine (hereinafter also named PLC for brevity) induces the phenomenon of programmed death (apoptosis)

in the cells. This effect allows the treatment of blood vessel pathologies based on the proliferation of smooth muscular cells of vessel walls, such as pulmonary hypertension, hypertension, restenosis after angioplasty or coronary stenting.

5        Advantageously, PLC is a well-known drug, whose side effects are quite limited. Examples of use of propionyl l-carnitine are US 4415589, US 4255449, IT 1155772, EP 0793962, EP 0811376, WO99/17623, PCT/IT97/00113.

      Accordingly, a first aspect of the present invention relates to  
10    the use of propionyl L-carnitine and the pharmacologically acceptable salts thereof for the preparation of a medicament useful in the treatment of pathologies whose treatment gains a benefit from inducement of apoptosis, in particular blood vessels, such as restenosis after angioplasty or coronary stenting, or in particular  
15    tumors.

      Another object of the present invention is the use of propionyl L-carnitine and the pharmacologically acceptable salts thereof for the preparation of a medicament useful for the treatment of hypertension.

20        Another object of the present invention is the use of propionyl L-carnitine and the pharmacologically acceptable salts thereof for the preparation of a medicament useful for the treatment of pulmonary hypertension.

      Still another aspect of the present invention is the use of  
25    propionyl L-carnitine and the pharmacologically acceptable salts

thereof for the preparation of a medicament useful to prevent restenosis after angioplasty or coronary stenting.

Also an object of the invention described herein is the co-ordinated use the propionyl L-carnitine according to which an  
5 adjuvant effect with the anticancer agent is obtained. As adjuvant effect it is intended a combination therapy of an antitumour drug and propionyl L-carnitine, by means of which, PLC exerts an apoptotic effect on the tumour cell, thus assisting the cytotoxic effect of the antitumour drug. In this way an improvement of the  
10 therapeutic index of the antitumour drug is expected.

A further object of the invention described herein is the use of propionyl L-carnitine in the preparation of a medicament useful for treating tumors.

Yet another object of the invention described herein are  
15 combinations the propionyl L-carnitine with anticancer agents and the related pharmaceutical compositions.

In the context of the invention described herein, what is meant by "co-ordinated use" of the aforesaid compounds is, indifferently, either (i) co-administration, i.e. the substantially simultaneous or  
20 sequential administration of propionyl L-carnitine or one of its pharmacologically acceptable salts and of an anticancer agent, or (ii) the administration of a composition comprising the aforesaid active ingredients in combination and in a mixture, in addition to optional pharmaceutically acceptable excipients and/or vehicles.

The invention described herein thus covers both the co-administration of propionyl L-carnitine or one of its pharmacologically acceptable salts and of the anticancer agent, and pharmaceutical compositions, which can be administered orally, parenterally or nasally, including controlled-release forms, comprising the two active ingredients in a mixture.

Though clear from the following detailed description of the invention, one can also envisage the co-ordinated use of an anticancer agent, such as for example, taxol, bleomycin, carboplatin, vincristine, a camptothecine. In all these embodiments, propionyl L-carnitine can be used in the co-ordinated use.

Co-administration also means a package, or manufactured article, comprising distinct administration forms of propionyl L-carnitine or one of its pharmacologically acceptable salts and of an anticancer agent, accompanied by instructions for the co-ordinated simultaneous or time-scheduled intake of the active ingredients according to a dosage regimen established by the primary care physician, on the basis of the patient's condition.

The embodiment of the invention described herein also contributes to healing and to prolonging the lives of the patients thanks to the increase in therapeutic success due to the possibility of maintaining the scheduled treatment protocols or of increasing the doses of the chemotherapeutic agent, without having to discontinue the treatment due to contraindications. It also possible

to foresee a reduction of the dose of the anticancer drug, thanks to the adjuvant effect of propionyl L-carnitine.

The medicament according to the present invention can be obtained admixing the active ingredient (propionyl L-carnitine or a pharmacologically acceptable salt thereof) with excipients suitable for formulation of compositions intended for enteral administration (in particular the oral one) or parenteral administration (in particular through intramuscular or intravenous route). All such excipients are well known to persons skilled in the art.

As pharmaceutically acceptable salt of propionyl L-carnitine, it is intended any salt thereof with an acid which does not give rise to unwanted side effects. These acids are well known to the pharmacologists and to the experts of pharmaceutical technology.

Non-limiting examples of said salts are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

Some examples of formulations in the form of unitary dosages are given.

**(a) Formulation for tablets**

A tablet contains:

**Active ingredient**

propionyl L-carnitine HCl	mg 500
---------------------------	--------

**Excipients**

Microcrystalline cellulose	mg 54.0
----------------------------	---------

	Polyvinylpyrrolidone	mg 18.0
	Crospovidone	mg 30.0
	Magnesium Stearate	mg 15.0
	Fumed silica	mg 3.0
5	Hydroxypropylmethylcellulose	mg 10.0
	Polyethylene glycole 6000	mg 2.5
	Titanium dioxide	mg 1.8
	Methacrylate copolymer	mg 8.3
	Talcum (trivalented)	mg 2.4

10 (b) **Formulation of intravenously injectable bottles**

A bottle contains:

**Active ingredient**

Propionyl L-carnitine HCl mg 300

**Excipient**

15 Mannitol mg 300

A solvent vial contains:

Sodium acetate 3·H<sub>2</sub>O mg 390

Water for injectable F.U. q. s. to ml 5

The medicament prepared according to the present invention  
 20 will be administered in the form of pharmaceutical composition,  
 which can be prepared according to the general common knowledge  
 of the person skilled in the art.

Depending on the administration route appropriately chosen,  
 oral, parenteral or intravenous; the pharmaceutical composition will  
 25 be in the suitable form.

Examples of pharmaceutical compositions, wherein the medicament according to the present invention is comprised, are the solid or liquid oral forms, such as tablets, all types of capsules, pills, solutions, suspensions, emulsions in the form of unitary or divided  
5 doses, syrups, ready-to-use or extemporaneous drinkable unit doses. Other examples are parenteral forms, injectable forms for intramuscular, subcutaneous or intravenous administration. Controlled or programmed release forms are also appropriate.

Dosages, posology and general therapeutic regimen will be  
10 determined by the physician according to his knowledge, patient's conditions and the pathology to be treated.

The association, whether co-administered in the same medicament or separately (at the same time or subsequently) of PLC with other active ingredients is also comprised in the present  
15 invention.

In a first preferred embodiment, the present invention relates to restenosis after angioplasty.

According to this first preferred embodiment, the pharmacological dose of PLC is such as not to exceed hematic  
20 concentration of 100 mM.

The following example further illustrates the invention.

### **EXAMPLE 1**

Wistar male rats, weighing between 270 and 290 mg, were used for the experiments. The rats were anaesthetised with  
25 Nembutal i.p. (35 mg/kg body weight) and the thoracic portion of

aorta was submitted to endothelium mechanical removal with Fogarty 2F balloon probe (Baxter USA), according to the Baugartner and Studer method(1966) with minor modification (Orlandi 1994). The animals were randomized into 5 groups, each group is reported  
5 in Table 1.

Two groups were subjected to pharmacological treatment with propionyl L-carnitine (PLC, 120 mg/Kg p.c. die), one group was treated with an ACE-inhibitor (Enalapril, 1 mg/Kg p.c. die); the two remaining groups were the control. Moreover, some non-balloonized  
10 animals were used as blanks.

**Table 1**

<b>Final number of Wistar rats</b>	<b>Treatment</b>	<b>Duration (days)</b>
7	de-endothelialization + PLC	3
7	de-endothelialization	3
8	de-endothelialization + ACE-antagonist	15
8	de-endothelialization + PLC	15
8	de-endothelialization	15
5	blanks	-

The animals were sacrificed 3 and 15 days after de-  
15 endothelialization. Two hours before sacrifice, all the rats received i.v. a Bromodeoxyuridine solution (BrDU) (45 mg/kg body weight) in order to verify cell proliferation. One hour before sacrifice, some



randomly selected animals received 1 ml Blue Evans (1% in 0.9% NaCl solution) in order to evaluate the degree of aorta disruption.

At sacrifice, the animals were anaesthetised with i.p. Nembutal and perfused, after washing with isotonic saline containing 3% Dextran 70, with buffered formalin for 20 minutes. Aortae were isolated, slightly washed in saline and dissected longitudinally. Carotid, heart and small intestine were also excised. All the organs were post-fixed in the same fixative for 24 hours at room temperature.

Some aortic fragments were used for electronic microscopy. Aortae were rolled up and included in paraffin. Serial sections having 5  $\mu$ m thickness were stained with Hematoxylin-Eosine, Verhoeff-Van Gieson and Movat's pentachromic and used for morphologic and morphometric studies.

In some non-perfused animals, fragments of aortic tissue were frozen in liquid nitrogen for the determination of tissular carnitines and for subsequent studies of molecular biology.

### **Immunohistochemical staining**

In order to put in evidence proliferating cells in damaged arteries, serial sections in paraffin of aortae were deparaffined, rehydrated, immersed in a 3% H<sub>2</sub>O<sub>2</sub> solution for 20 minutes and incubated with trypsin (0,05 M in Tris-HCl, pH 7.6) at 37°C. After that, sections were treated with 2N HCl at 37°C for 30 minutes, washed with 0.1 M sodium tetraborate for 10 minutes, incubated with normal horse serum (Vector) and subsequently with anti-BrDU

monoclonal antibody (Ylem) for 1 hour. The preparates were then reacted with biotilinated anti-mouse IgG (Vector) and the Streptoavidine-ABC-POD complex (Ylem).

The reaction was evidenced by using diaminobenzidine (DAB) as final chromogen. The count of positive nuclei for BrDU was made on the total number of nuclei. Such count was blind-made by two researchers separately. The difference between the two counts was always lower than 0.5%.

All data were analysed with the T Student's test. The differences between the groups were considered to be significant for  $P < 0.05$ .

### **Morphometric analysis**

The entity of intima thickening after 15 days was evaluated on Verhoeff-Van Gieson stained sections, using a grid overlapped on the image, consisting of 400 points, 1 cm from each other.

The analysis was made on hystological preparates through a Hamamatsu C3077 camera controlled by a Hamamatsu DVS 3000 image analyser and connected to a Polyvar-Reichert microscope. Morphometric evaluation was made at X116 magnification. The following parameters were evaluated a) relative volume of intima referred to arterial wall; b) relative volume of tunica media referred to arterial wall, by counting the overlapping points on the intima and mean tunica.

3-12 aorta sections were used at different level for each animal. This number was a function of the structure sizes, according to

Sach's formula, showing the number of fields necessary to obtain a statistically significant sample.

### **Ultrastructural studies**

Small aorta samples were selected for electronic microscopy.  
5 Aortae were post-fixed in osmium tetroxide and embedded in EPON 812. Ultra thin sections were stained with uranyl acetate followed by lead citrate and examined using a Hitachi H-7100 FA transmission electronic microscope.

### **Tissular and plasma carnitine assay**

10 2-3 ml of blood samples were withdrawn from each animal before mechanical de-endothelialization and at the time of sacrifice. Plasma was separated by centrifugation (300 rpm) for 20 minutes and frozen for plasmatic carnitine assay according to the Pace et al. method.

15 Aorta wall samples were withdrawn from some non-perfused animals, randomly selected from each group, frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  for the carnitine assay, according to the above Pace et al. reference.

## **RESULTS**

### **Ultrastructural studies**

Small aorta samples were selected for electronic microscopy.  
Aortae were post-fixed in osmium tetroxide and embedded into EPOC 812. Ultra thin sections were stained with uranyl acetate followed by lead citrate and examined through a Hitachi H-7100 FA  
25 transmission electron microscope.

### **Tissular and plasmatic carnitine assay**

2-3 ml blood samples were withdrawn from each animal before mechanical de-endothelialization and just before sacrifice. Plasma was separated by centrifugation (3000 rpm) for 20 minutes and  
5 frozen for the plasmatic carnitine assay according to the Pace et al. method.

Samples of aortic wall were taken from some non-perfused animals, randomly selected from each group, frozen in liquid nitrogen and kept at  $-80^{\circ}\text{C}$  for the assay of tissutal carnitines  
10 according to the above-mentioned Pace et al. method.

## **RESULTS**

### **Lesion morphology**

3 days after the mechanical lesion, rat aortae did not show significant hystological alterations, except the lack of endothelial cell  
15 coating.

15 days after, remodelling of arteria could be observed for the presence of an intima thickening (or neointima), consisting in round or lengthened cells immersed in abundant extracellular matrix. Immune hystochemical study put in evidence in particular the  
20 presence of abundant smooth muscular cells (SMC) inside neointima.

### **Studies on proliferation**

a) **3 days after de-endothelialization:** the count of anti-BrDU staining positive nuclei showed substantial differences  
25 between the two groups examined. Quantitative analysis (Table 2)

puts in evidence that the number of BrDU-positive nuclei is significantly lower in the tunica media in the PLC-treated animals, with respect to controls (59.3% reduction against control,  $p < 0.02$ ). In both groups the distribution of BrDU-positive nuclei is more concentrated in the lumen portion of mean tunica with respect to the adventitia portion, with a 2:1 ratio.

b) **15 days after de-endothelialization:** Table 3 shows that in each group the proliferation index of SMCs is significantly higher ( $p < 0.001$ ) in the intima with respect to the tunica media. No significant differences are observed in the number of BrDU-positive nuclei, in the intima and tunica media, by comparing PLC, Enalapril and control animals.

### **Morphometric analysis**

As described in Table 3, after 15 days from endothelial lesion, the intima relative volume is significantly lower, both in the PLC-treated (31.11% reduction against control,  $p < 0.02$ ) and ACE-antagonist-treated (26.14% reduction against control,  $p < 0.01$ ) animals against control animals.

### **Table 2**

In-vivo treatment with propionyl L-carnitine (PLC) on the proliferation of smooth muscle cells of rat aorta after mechanical de-endothelialization: percentage of proliferating cell nuclei (anti-bromodeoxyuridine positive) after 3 days ( $\pm$  s.e.m)

	interval	positive nuclei/ total nuclei %	Reduction %	Difference
Mean tunica Control animals	3 days	6.36 + 1.27		
Tunica media PLC treated animals	3 days	2.59 ± 0.56	59.3	P<0.02

**Table 3**

In vivo treatment with propionyl L-carnitine (PLC) and with the ACE-antagonist Enalapril on the proliferation of smooth muscular cells of rat aorta after mechanical de-endothelialization: percentage of proliferating cells (anti-bromodeoxyuridine positive) and percentage ratio between intima volume and aorta wall volume after 15 days (± s.e.m.) (preliminary results).

10

	interval	+ Nuclei/total nuclei %	Intima volume/ wall	Reduction (% to CTR)
Intima tunica, control animals	15 days	2.65 ± 0.44 (a)	29.73 ± 1.54	
Intima tunica, PLC treated animals	15 days.	1.99 + 0.32 (b)	20.48 ± 2.73 (d)	31.11
Intima tunica, enalapril treated animals	15 days	2.43 ± 0.39 (c)	21.96 ± 1.20 (e)	26.14
Tunica media, control	15 days	0.24 ± 0.05		

animals				
Tunica media, PLC treated animals	15 days	0.24 ± 0.09		
Tunica media, enalapril treated animals	15 days	0.27 ± 0.09		
Tunica media, non peeled animals		0.24 ± 0.05		

(a) intima vs tunica media:  $p < 0.0001$ ; (b) intima vs tunica media:  $p < 0.0001$ ; (c) intima vs tunica media:  $p < 0.001$ ; (d) intima vol./wall vs controls:  $p < 0.02$ ; (e) intima vol/wall vs controls:  $p < 0.01$

#### 5      **EFFECT OF PROPIONYL L-CARNITINE IN THE CONTROL OF PROLIFERATION/APOPTOSIS.**

In vitro experiments were carried out to evaluate the effect of propionyl L-carnitine (PLC) on smooth muscular cells (SMC) isolated from aortae of spontaneously hypertensive rats (SHR) and, as  
10 control, on SMC isolated from normotensive rats (WKY).

These in vitro studies evidenced that PLC, when administered during culture exponential growth phase, reduces cell growth, evaluated as cell number/ml, as well as DNA synthesis, evaluated through incorporation of tritiated thymidine (Tab. 4 and 5).

15

**Table 4:** cell number/ml at culture days 2, 3, 4 and 6

	Day 2	Day 3	Day 4	Day 6
SHR CTRL	$5 \cdot 10^4 \pm 2$	$15 \cdot 10^4 \pm 3$	$28 \cdot 10^4 \pm 7$	$42 \cdot 10^4 \pm 7$
SHR PLC	$7 \cdot 10^4 \pm 4$	$4 \cdot 10^4 \pm 2$	$7 \cdot 10^4 \pm 4$	$20 \cdot 10^4 \pm 5$
WKY CTRL	$4 \cdot 10^4 \pm 1$	$2 \cdot 10^4 \pm 2$	$7 \cdot 10^4 \pm 2$	$13 \cdot 10^4 \pm 4$
WKY PLC	$3 \cdot 10^4 \pm 2$	$4 \cdot 10^4 \pm 2$	$6 \cdot 10^4 \pm 2$	$8 \cdot 10^4 \pm 3$

**Table 5:** tritiated thymidine incorporation at culture day 6

	$\mu\text{Ci}/\mu\text{gDNA}$
SHR CTRL	2.99 E-05
SHR PLC	1.81 E-05
WKY CTRL	2.1 E-05
WKY PLC	2.56 E-05

5 As a further characterisation of smooth muscular cells in the presence of PLC, the percentage of apoptotic cells was measured both in basal conditions and in oxidative stress conditions. Apoptosis evaluation was carried out by counting the number of apoptotic cells present on a total of 1000 cells, after specific DNA  
 10 staining with Hoechst 33258. The results of this experiment demonstrated that, in SHR cultures, PLC determines a significant increase of apoptosis percentage in basal conditions and that this increase is more evident under stress conditions.

In WKY cultures, apoptosis percentage is negligible (tab. 6)



**Table 6:** apoptotic cell percentage in basal conditions and under oxidative stress.

	<b>Basal conditions</b>	<b>Oxidative stress</b>
SHR CTRL	0	2
SHR PLC	2	10
WKY CTRL	0	0
WKY PLC 2	0	2

5

The behaviour observed in SHR smooth muscular cells might be in some way related to the deregulated expression of c-myc, which characterises spontaneously hypertensive rats (Negoro et al., 1988). Moreover, it was observed that c-myc actively cooperates in inducing apoptosis subsequently to a proliferation stop (Bennet et al., 1993; Bissonette et al., 1993), accordingly the data shown above suggest that PLC anti-proliferative effect may be related to an interference with DNA replication.

10

## **EXAMPLE 2**

15

### **Cell lines**

20

Human derived neoplastic cell, obtained from Istituto Zooprofilattico of Brescia, were cultivated. The cells used for the experiment were: U266, multiple myeloma, HeLa, uterine cervix tumor, K562, chronic myeloid leukemia cells. HeLa and K562 were cultivated in RPMI+10% FCS, while those of U266 line were

cultivated in RPMI+15% FCS, both media containing Penicilline/Streptomycine (50 U/mL and 50 µg/mL). Cells were plated in 6-wells plates (Falcon). Analysis were performed in cells having 50% confluence.

5 Each cell line was treated with PCL according to the following schemes:

a) 1 mM PLC for 24 hours (figures 1-3);

1 mM PLC for 48 hours (figures 1-3);

b) 1 mM PLC for 24 hours, followed by 24 hours media  
10 without molecules (figures 4-6).

At the end of each treatment, cells were counted in Burker chamber in the presence of Trypan Blue 0.5%, diluted 1:2. Count was made for each experimental group on samples coming from three wells.

15 The treatment of neoplastic cell lines of human origin with 1 mM propionyl L-carnitine show the capacity of inhibiting the proliferation both after 24 hours and after 48 hours. In particular inhibition was respectively 25% and 17% after 24 and 48 hours with respect to the control for HeLa; 46% and 26% after 24 and 48 hours  
20 with respect to the control for U266; 37% and 39% after 24 and 48 hours with respect to the control for K562.

PLC inhibition effect persists after having removed the substances from cultivation medium. In fact, in this case cells werer treated for 24 hours with 1 nM PLC, then the medium contining PLC  
25 was removed and fresh medium was added without the substance.

Inhibition values were 20%, 26% and 21% for HeLa, U266 and K562, respectively.

**References:**

Spagnoli L.G. Giorn. Arterioscl. 1983; 8: 117-145

Asai K, Funaki C, Hayashi T. et al. Arterioscl. Thromb. 1993;  
13: 892-899

5 Baumgartner H.R., Studer A, Pathol. Microbiol. (Base) 29: 393-  
405, 1966

Bennet M.R., Evan G.I., Newby A.C., Circ. Res. 1994; 74:525-  
536

Bissonette R.P., Shi Y., Mahboubi A., Glynn J.M. and Green  
10 D.R, Curr. Commun. Cell. Mol. Biol. 1993

Bonanno E., Ghibelli L., Coppola S., Spagnoli L.G.,  
International Conference on Cell Death in Human Pathology. Lecce,  
June 22-25, p. 54, 1995

Bouchaton-Piallat M.L., Gabbiani F., Desmouliere A. and  
15 Gabbiani G. Am. J. Pathol. 146: 1059-1064, 1995

Cavallero C., De Lellis C., Di Tondo U. et al. In: Cavallero C.,  
editor. The arterial wall in atherogenesis. Padova: Piccin Medical  
Book, 1975: 25-42

Cavallero C., Di Tondo U. Mingazini L. et al., Atherosclerosis  
20 1973; 17: 49-62

Cavallero C., Di Tondo U., Mingazzini P. et al. Atherosclerosis  
1976; 25: 145-152

Cavallero C., Turolla E. and Ricevuti G., Atherosclerosis 1971;  
13: 9-20

- Cheung W.T., Shi M.N., Young J.D. et al., *Biochem. Pharmacol.* 1987; 36: 2183-2189
- Clowes A.W., Schwartz S.M., *Cir. Res.* 56: 139-145, 1985
- Corsini A., Raiteri M., Soma M. et al., *Pharmacol. Res.* 1991;  
5 23: 173-180
- Curi R., Bond J.A., Calder P.C. and Newsholme E.A., *Gen. Pharmac.* 1993; 24, 591-597
- Holmes D.R.J., Vliestra R.E., Smith H.C., *Am. J. Cardiol.* 1984;  
77C-81C.
- 10 Kerr J.F.R., Winterford C.M., Harmon B.V., *Cancer* 73: 2013-2026, 1994
- Llera-Moya M., Rothblat G.H., Glick J.M. et al., *Arterioscler. Thromb.* 1992; 12: 1363-1370
- Mauriello A., Sangiorgi G., Orlandi A., Schiaroli S., Pertumo S.,  
15 Spagnoli L.G.,
- Negoro N., Inariba H., Inoue T., Kanayama Y., Takeda T.
- Olsson A.G., Ruhn G., Erikson U., *J. Int. Med.* 227: 381, 1 990
- Orlandi A., Ehrlich H.P., Ropraz P. et al., *Arterioscler. Thromb.*  
1994; 14: 982-989
- 20 Orlandi A., Ropraz P. and Gabbiani G., *Exp Cell Res* 1994;  
214: 528-536
- Powell J.S., Clozel J-P., Muller R.K.M., Kuhn H., Hefti F.,  
Hosang M., Baumgarner H., *Science* 245: 186-188, 1989
- Ross R., Glomset J.A., *N. Engl. J. Med.* 295: 369-377, 1976

Schwartz S.M., Heimark R.L., Majesky M.V., *Physiol. Rev.* 70:  
1177-1209, 1990

Spagnoli L.G., *Giorn. Arterioscl.* 1983; 8: 117-145

Spagnoli L.G., Orlandi A., Marino B., Mauriello A., De Angelis  
5 C., Ramacci M.T., *Atherosclerosis* 1995; 114, 29-44

Spagnoli L.G., Orlandi A., Marino B. et al., *Atherosclerosis*  
1995; 114: 29-44

Spagnoli L.G., Orlandi A., Mauriello A., et al., *Pathol. Res.*  
*Pract.* 1992; 4-5: 637642

10 Spagnoli L.G., Orlandi A., Mauriello A. et al. *Atherosclerosis*  
1991; 89: 11-24.

Spagnoli L.G., Palmieri G., Mauriello A. et al., *Atherosclerosis*  
1990; 82: 27-36

Spagnoli L.G., Sambuy Y., Palmieri G. et al., *Artery* 1985; 13:  
15 187-198

Stein O., Halperin G., Stein Y., *Arteriosclerosis* 1987; 7:  
585-592

**CLAIMS**

1. Use of propionyl L-carnitine or a pharmaceutically acceptable salts thereof for the preparation of a medicament useful in the treatment of pathologies whose treatment gains a benefit from  
5 inducement of apoptosis.

2. Use according to claim 1, wherein said medicament is useful for the treatment of hypertension.

3. Use according to claim 1, wherein said medicament is useful for the treatment of pulmonary hypertension.

10 4. Use according to claim 1, wherein said medicament is useful for the prevention of restenosis after angioplasty or coronary stenting.

5. Use according to claim 1, wherein said medicament is useful for the treatment of tumors.

15 6. Use according to anyone of claims 1 to 5, wherein said salt of propionyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and  
20 acid tartrate.

7. Combination comprising an antitumour drug and propionyl L-carnitine.

8. Use of the combination according to Claim 7 for the preparation of a medicament with anticancer activity, characterised  
25 in that said medicament comprises an effective amount of propionyl

L-carnitine which exerts an adjuvant action for the anticancer activity.

9. A package, or manufactured article, comprising distinct administration forms of propionyl L-carnitine, or one of its  
5 pharmacologically acceptable salts and of an anticancer agent, accompanied by instructions for the co-ordinated simultaneous or time-scheduled intake of the active ingredients.



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 99/00357

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/22 A61P9/12 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NERI ET AL.: "Differences between carnitine derivatives and coenzyme Q-10 in preventing in-vitro doxorubicin-related cardiac damages" ONCOLOGY, vol. 45, no. 3, 1988, pages 242-246, XP000872620 * see in particular Figure 1 *	7-9
Y	WO 97 34596 A (MORETTI SONIA ;MENDES SRL (IT)) 25 September 1997 (1997-09-25) *see in particular claims 1-4,10 *	1-9
Y	EP 0 681 839 A (KURATSUNE HIROHIKO ;KITANI TERUO (JP)) 15 November 1995 (1995-11-15) * see in particular column 6, lines 27-53; column 5, lines 9-34 *	1-9
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 March 2000

Date of mailing of the international search report

09/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Isert, B

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 99/00357

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>L G SPAGNOLI ET AL:            "Propionyl-L-carnitine prevents the            progression of atherosclerotic lesions in            aged hyperlipemic rabbits"            ATHEROSCLEROSIS,NL,AMSTERDAM,            vol. 114, no. 1, 1995, pages 29-44,            XP002101594            ISSN: 0021-9150            cited in the application            * see in particular the abstract *</p> <p style="text-align: center;">---</p>	1-9
Y	<p>MAURIELLO ET AL.: "Effect of long-term            treatment with propionyl-l-carnitine on            smooth muscle cell polyploidy in            spontaneously hypertensive rats"            HYPERTENSION,            vol. 28, no. 2, 1996, pages 177-182,            XP000872723            * see in particular the abstract *</p> <p style="text-align: center;">---</p>	1-9
Y	<p>US 5 786 326 A (HORWITZ LAWRENCE D)            28 July 1998 (1998-07-28)            * see the abstract *</p> <p style="text-align: center;">-----</p>	1-9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 99/00357

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9734596 A	25-09-1997	IT RM960171 A CA 2248879 A EP 0888113 A	15-09-1997 25-09-1997 07-01-1999
EP 0681839 A	15-11-1995	JP 8026987 A US 5576348 A	30-01-1996 19-11-1996
US 5786326 A	28-07-1998	US 5721209 A AU 6322898 A WO 9834619 A AU 699916 B AU 4674496 A CA 2185661 A CN 1145588 A CZ 9602889 A EA 960078 A EP 0754044 A HU 9603036 A WO 9623502 A PL 316612 A US 5837677 A US 5994346 A	24-02-1998 26-08-1998 13-08-1998 17-12-1998 21-08-1996 08-08-1996 19-03-1997 16-04-1997 30-09-1997 22-01-1997 28-05-1997 08-08-1996 20-01-1997 17-11-1998 30-11-1999